DD128332A5 - Verfahren zur herstellung von verbindungen mit antidepressiver wirkung - Google Patents

Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Info

Publication number
DD128332A5
DD128332A5 DD7600191893A DD19189376A DD128332A5 DD 128332 A5 DD128332 A5 DD 128332A5 DD 7600191893 A DD7600191893 A DD 7600191893A DD 19189376 A DD19189376 A DD 19189376A DD 128332 A5 DD128332 A5 DD 128332A5
Authority
DD
German Democratic Republic
Prior art keywords
preparing compounds
antidepressive effect
antidepressive
effect
preparing
Prior art date
Application number
DD7600191893A
Other languages
German (de)
English (en)
Inventor
Hendricus B A Welle
Volkert Claassen
Original Assignee
Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Nv filed Critical Philips Nv
Publication of DD128332A5 publication Critical patent/DD128332A5/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD7600191893A 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung DD128332A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
DD128332A5 true DD128332A5 (de) 1977-11-09

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DD7600191893A DD128332A5 (de) 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (en, 2012)
JP (1) JPS6026776B2 (en, 2012)
AR (2) AR211011A1 (en, 2012)
AT (1) AT340895B (en, 2012)
AU (1) AU505358B2 (en, 2012)
BE (1) BE839744A (en, 2012)
CA (1) CA1076142A (en, 2012)
CH (4) CH626057A5 (en, 2012)
DD (1) DD128332A5 (en, 2012)
DE (1) DE2610886A1 (en, 2012)
DK (1) DK144942C (en, 2012)
ES (1) ES446192A1 (en, 2012)
FI (1) FI61875C (en, 2012)
FR (1) FR2304336A1 (en, 2012)
GB (1) GB1535226A (en, 2012)
GR (1) GR60052B (en, 2012)
HU (1) HU171030B (en, 2012)
IE (1) IE43768B1 (en, 2012)
IL (1) IL49238A (en, 2012)
IT (1) IT1063064B (en, 2012)
MX (1) MX9203723A (en, 2012)
NL (1) NL7503310A (en, 2012)
PL (3) PL100614B1 (en, 2012)
SE (1) SE410312B (en, 2012)
SU (3) SU635867A3 (en, 2012)
YU (1) YU39345B (en, 2012)
ZA (1) ZA761434B (en, 2012)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
IN182588B (en, 2012) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (en, 2012) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
EP1276478A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス, インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
EP1871358A1 (en) 2005-04-22 2008-01-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
PE20070093A1 (es) * 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
KR101521405B1 (ko) * 2005-07-19 2015-05-18 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신 길항물질
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HUE028650T2 (en) 2009-10-23 2016-12-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
EP3351104B1 (en) 2010-07-01 2020-12-09 Azevan Pharmaceuticals, Inc. Compounds for use in the treatment of intermittent explosive disorder
EP2685966A1 (en) 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
EP2981518B1 (en) 2013-04-03 2021-03-03 ZCL Chemicals Ltd. "an improved process for the preparation of fluvoxamine maleate"
HRP20210114T1 (hr) 2014-02-07 2021-04-16 Támogatott Kutatócsoportok Irodája Nova primjena spoja agonista sigma-1 receptora
CN116327950A (zh) 2014-03-28 2023-06-27 阿泽范药品公司 组合物用于治疗神经退行性疾病的神经精神症状的用途
IL288321B1 (en) * 2016-03-10 2025-04-01 Janssen Pharmaceutica Nv Methods for treating depression using orexin-2 receptor antagonists
EP3544420B8 (en) 2016-11-24 2022-11-23 Sigmadrugs Kutató Korlátolt Felelösségü Társaság Use of compositions for organ/tissue preservation
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
YU39345B (en) 1984-10-31
AR211011A1 (es) 1977-10-14
FR2304336A1 (fr) 1976-10-15
ATA195476A (de) 1977-05-15
ZA761434B (en) 1977-10-26
JPS51125345A (en) 1976-11-01
DK144942C (da) 1982-12-06
DK115976A (da) 1976-09-21
DE2610886A1 (de) 1976-10-07
IL49238A0 (en) 1976-05-31
GR60052B (en) 1978-04-04
US4085225A (en) 1978-04-18
FI760699A7 (en, 2012) 1976-09-21
PL100614B1 (pl) 1978-10-31
PL101951B1 (pl) 1979-02-28
CH626057A5 (en, 2012) 1981-10-30
JPS6026776B2 (ja) 1985-06-25
FR2304336B1 (en, 2012) 1979-09-28
NL7503310A (nl) 1976-09-22
ES446192A1 (es) 1977-10-01
CA1076142A (en) 1980-04-22
DE2610886C2 (en, 2012) 1987-09-24
AU505358B2 (en) 1979-11-15
YU71476A (en) 1982-10-31
CH629477A5 (de) 1982-04-30
GB1535226A (en) 1978-12-13
AU1214776A (en) 1977-09-22
AT340895B (de) 1978-01-10
SU645559A3 (ru) 1979-01-30
CH629184A5 (de) 1982-04-15
CH629761A5 (de) 1982-05-14
HU171030B (hu) 1977-10-28
SU635867A3 (ru) 1978-11-30
MX9203723A (es) 1992-07-01
DK144942B (da) 1982-07-12
SE410312B (sv) 1979-10-08
FI61875B (fi) 1982-06-30
PL100052B1 (pl) 1978-08-31
IE43768L (en) 1976-09-20
IT1063064B (it) 1985-02-11
BE839744A (fr) 1976-09-20
SU620206A3 (ru) 1978-08-15
FI61875C (fi) 1982-10-11
SE7603341L (sv) 1976-09-21
AR211153A1 (es) 1977-10-31
IL49238A (en) 1978-08-31
IE43768B1 (en) 1981-05-20

Similar Documents

Publication Publication Date Title
DD128332A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD130857A5 (de) Verfahren zur herstellung von n-phosphonomethylglycintriestern
DD131931A5 (de) Verfahren zur herstellung von spiro-hydantoin-verbindungen
DD129330A5 (de) Verfahren zur herstellung von antitumorsubstanzen
DD127928A5 (de) Verfahren zur herstellung heterocyclischer verbindungen
DD131649A5 (de) Verfahren zur herstellung von n-(perfluoracyl)-n-phosphono-methyl-glycin-verbindungen
DD131858A5 (de) Verfahren zur herstellung von 3-chlorcephemverbindungen
DD130036A5 (de) Verfahren zur herstellung von optisch aktiven 11-desoxy-16-aryloxy-omega-tetranorprostaglandinen
DD129326A5 (de) Verfahren zur herstellung von 1,4-diphenyl-3-pyrazolin-5-onen
AT341668B (de) Verfahren zur herstellung von 7-aminocephemverbindungen
AT342191B (de) Verfahren zur herstellung von arzneimittelkombinationen
AT333305B (de) Verfahren zur herstellung von phosphonothioureidoverbindungen
DD128330A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD131562A5 (de) Verfahren zur herstellung von 5-pregnen-derivaten
DD122961A5 (de) Verfahren zur herstellung von diphenylaether-derivaten
AT352914B (de) Verfahren zur herstellung von polyen- verbindungen
DD122976A5 (de) Verfahren zur herstellung von pyridoepoxyaethanen
DD122964A5 (de) Verfahren zur herstellung von prostensaeurederivaten
DD128329A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
AT339268B (de) Verfahren zur herstellung von acetoxybutanolen
DD133327A5 (de) Verfahren zur herstellung von organischen verbindungen
AT350199B (de) Verfahren zur herstellung von 17-monoestern von 17alfa,21-dihydroxysteroiden
DD133147A5 (de) Verfahren zur herstellung antihelmintischer verbindungen
AT338775B (de) Verfahren zur herstellung von 4-oxa-5-hydroxypolycycloalken-3-onen
DD128709A5 (de) Verfahren zur herstellung von dekahydrochinolinderivaten